Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on MedinCell SA (MEDCL – Research Report), retaining the price target of €25.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ram Selvaraju’s rating is based on MedinCell SA’s strong performance and promising future prospects. The company has seen impressive sales figures for UZEDY, an extended-release injectable for schizophrenia, surpassing both its own and Teva Pharmaceuticals’ expectations. This success has resulted in significant royalty revenue for MedinCell, which is expected to grow further. Additionally, the completion of the pivotal Phase 3 trial for TEV-44749, another long-acting injectable developed with MedinCell’s technology, marks a critical milestone. TEV-44749 met its primary efficacy endpoint, and its safety profile appears favorable, which bodes well for future regulatory approval and commercialization.
Furthermore, the strategic partnership with Teva Pharmaceuticals strengthens MedinCell’s market position by targeting widely-used atypical antipsychotic categories. The combination of UZEDY’s robust market uptake and the potential launch of TEV-44749 positions MedinCell to capture a significant share in the long-acting injectable market. This dual product strategy minimizes the risk of market cannibalization due to the distinct patient profiles for risperidone and olanzapine, enhancing MedinCell’s growth trajectory. As a result, these factors contribute to Ram Selvaraju’s optimistic Buy rating for MedinCell SA.
In another report released on February 7, Kepler Capital also maintained a Buy rating on the stock with a €18.30 price target.